Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 375

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 375
---
 with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. It also evaluates over 119 RNA fusions linked to leukemia development. The test simultaneously analyzes DNA for point mutations, small deletions, insertions, and copy number variants (such as SNVs, indels, CNVs), and RNA for chromosomal rearrangements, providing a comprehensive genetic profile in one single sample. The precise identification of genetic alterations enables informed diagnosis, patient stratification, and the selection of personalized treatments based on specific genomic events. 186 Genetic and Rare Diseases: Chromosomal Microarray (“CMA”) CMA detects genetic anomalies and syndromes not identifiable through conventional karyotyping (chromosome imaging). This diagnostics service is especially adept at analyzing chromosome structure, copy number, and segregation, thus offering critical insights into a wide range of disorders, including cancers, developmental conditions, and fetal anomalies. The test requires a blood sample and is geared towards pediatric patients with complex diagnoses, individuals with developmental delays, intellectual disabilities, autism spectrum disorder, congenital anomalies, and those with a history of multiple pregnancy losses. Genetic and Rare Diseases: Clinical Exome This genetic test is designed to diagnose rare genetic disorders by evaluating the exons of up to 6,704 genes, which may explain symptoms associated with undiagnosed diseases. It utilizes blood samples and is available for individual patients or in a trio format that includes samples of the patient’s biological parents. This test is appropriate for preconception, neonatal, childhood, and adult patients, particularly those with rare Mendelian diseases or conditions with significant genetic heterogeneity and overlapping or nonspecific phenotypes. In addition, secondary findings are reported by request. Microbiome: Gut Screening Test This screening test tracks 28 selected biomarkers in the gut microbiome from relevant ecological metrics such as diversity, richness and balance to insightful metabolic capacity metrics such as short chain fatty acids production, vitamins production, Lipopolysaccharides production and other metrics related to the influence of gut microbiome in low grade chronic inflammation process. The test compares the patient’s metrics to our proprietary database of reference individuals who have healthy habits to identify potential dysbiosis processes. This allows gastroenterologists and related physicians to identify and monitor progress in treatments and conditions. Commercial Operations We currently offer our Heritas products in Argentina and Paraguay, while our Rewell products are available in Argentina. We expect to expand our business development initiatives and the offering of our services to Mexico and the rest